Abstract:miRNAs play important roles in modulating gene expression in varying cellular processes and disease pathogenesis, including neurodegenerative diseases. Several miRNAs are expressed in the brain, control brain development and are identified as important biomarkers in the pathogenesis of motor-and neuro-cognitive diseases such as Alzheimer's (AD), Huntington's and Parkinson's diseases (PD) and amyotrophic lateral sclerosis. These remarkable miRNAs could be used as diagnostic markers and therapeutic targeting potential for many stressful and untreatable progressive neurodegenerative diseases. To modulate these miRNA activities, there are currently two strategies involved; first one is to therapeutically restore the suppressed miRNA level by miRNA mimics (agonist), and the other one is to inhibit miRNA function by using anti-miR (antagonist) to repress overactive miRNA function. However, RNAi-based therapeutics often faces <i>in vivo</i> instability because naked nucleic acids are subject to enzyme degradation before reaching the target sites. Therefore, an effective, safe and stable bio-responsive delivery system is necessary to protect the nucleic acids from serum degradation and assist their entrance to the cells. Since neuronal cells are non-regenerating, to design engineered miRNAs to be delivered to the central nervous system (CNS) for long term gene expression and knockdown is representing an enormous challenge for scientists. This article provides an insight summary on some of the innovative strategies employed to deliver miRNA into target cells. These viral and non-viral carrier systems hold promise in RNA therapy delivery for neurodegenerative diseases.

MiRNA-based therapeutic potential in multiple sclerosis

MicroRNA in Multiple Sclerosis

Roles of miRNA, lcnRNA, and circRNA and Their Implications in Cellular Pathways

Stem Cell-Derived Exosomal MicroRNAs as Novel Potential Approach for Multiple Sclerosis Treatment

Development of Microrna-Based Therapeutics for Central Nervous System Diseases.

The role of microRNAs involved in the disorder of blood–brain barrier in the pathogenesis of multiple sclerosis

miRNAs Participate in MS Pathological Processes and Its Therapeutic Response.

Myeloid-derived Suppressor Cells and Multiple Sclerosis

Advances in MicroRNA Therapeutics: From Preclinical to Clinical Studies

Nanosystems and exosomes as future approaches in treating multiple sclerosis

MicroRNAs associated with the pathogenesis of multiple sclerosis

Recent Advances in Nanomedicines for Multiple Sclerosis Therapy.

Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple Sclerosis

Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis

Immunomodulatory Therapies of Multiple Sclerosis

MicroRNAs As T Lymphocyte Regulators in Multiple Sclerosis

MicroRNAs and their Implications in CD4+ T-cells, Oligodendrocytes and Dendritic Cells in Multiple Sclerosis Pathogenesis

Multiple sclerosis treatments a review of current biomedical engineering approaches

Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis

A review of possible therapies for multiple sclerosis

Getting miRNA Therapeutics into the Target Cells for Neurodegenerative Diseases: A Mini-Review